Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC

NCT07093762 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Atezolizumab+Bevacizumab+Carboplatin+Paclitaxel

Sponsor

Fuzhou General Hospital

Collaborators

[object Object]